Literature DB >> 20361010

Cerebrospinal fluid biomarkers of Alzheimer's disease.

Anne M Fagan1, David M Holtzman.   

Abstract

Alzheimer's disease will reach epidemic proportions within the next 20-30 years if left unchecked. Currently, there are no treatments that prevent or slow Alzheimer's disease but many are being developed. Parallel efforts to develop biomarkers to aid in disease diagnosis and prognosis, and assess disease risk are currently underway. Clinicopathological and biomarker studies have demonstrated that Alzheimer's disease pathology can be detected preclinically. Using biomarkers to identify affected individuals prior to the onset of clinical symptoms and associated synaptic/neuronal loss should enable novel clinical trial design and early mechanism-based therapeutic intervention. This article summarizes the most promising cerebrospinal fluid biomarkers, highlights novel applications and current challenges, and provides a prediction on how the field may evolve in 5-10 years.

Entities:  

Keywords:  Alzheimer’s disease; amyloid-β; biomarkers; cerebrospinal fluid; preclinical Alzheimer’s disease; tau

Mesh：

Substances：

Year:  2010        PMID： 20361010      PMCID： PMC2846664          DOI： 10.2217/BMM.09.83

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


  83 in total

1.  Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.

Authors:  Michael Ewers; Zhenyu Zhong; Katharina Bürger; Anders Wallin; Kaj Blennow; Stefan J Teipel; Yong Shen; Harald Hampel
Journal:  Brain       Date:  2008-03-11       Impact factor: 13.501

2.  [Overview on Alzheimer's disease].

Authors:  Yasuo Ihara
Journal:  Rinsho Shinkeigaku       Date:  2007-11

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

Authors:  Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

5.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

6.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

7.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

8.  Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

Authors:  M Bibl; B Mollenhauer; P Lewczuk; H Esselmann; S Wolf; C Trenkwalder; M Otto; G Stiens; E Rüther; J Kornhuber; J Wiltfang
Journal:  Mol Psychiatry       Date:  2007-03-06       Impact factor: 15.992

Review 9.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

10.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.

Authors:  K Buerger; S J Teipel; R Zinkowski; K Blennow; H Arai; R Engel; K Hofmann-Kiefer; C McCulloch; U Ptok; R Heun; N Andreasen; J DeBernardis; D Kerkman; H- J Moeller; P Davies; H Hampel
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910
View more
  27 in total

Review 1.  Homeostatic disinhibition in the aging brain and Alzheimer's disease.

Authors:  Marc Gleichmann; Vivian W Chow; Mark P Mattson
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

2.  Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.

Authors:  Catherine M Roe; Anne M Fagan; Elizabeth A Grant; Daniel S Marcus; Tammie L S Benzinger; Mark A Mintun; David M Holtzman; John C Morris
Journal:  Arch Neurol       Date:  2011-09

3.  Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

Authors:  Jewell B Thomas; Matthew R Brier; Randall J Bateman; Abraham Z Snyder; Tammie L Benzinger; Chengjie Xiong; Marcus Raichle; David M Holtzman; Reisa A Sperling; Richard Mayeux; Bernardino Ghetti; John M Ringman; Stephen Salloway; Eric McDade; Martin N Rossor; Sebastien Ourselin; Peter R Schofield; Colin L Masters; Ralph N Martins; Michael W Weiner; Paul M Thompson; Nick C Fox; Robert A Koeppe; Clifford R Jack; Chester A Mathis; Angela Oliver; Tyler M Blazey; Krista Moulder; Virginia Buckles; Russ Hornbeck; Jasmeer Chhatwal; Aaron P Schultz; Alison M Goate; Anne M Fagan; Nigel J Cairns; Daniel S Marcus; John C Morris; Beau M Ances
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

Review 4.  Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis.

Authors:  Matthew R Brier; Jewell B Thomas; Beau M Ances
Journal:  Brain Connect       Date:  2014-06

Review 5.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

6.  Aβ40 has a subtle effect on Aβ42 protofibril formation, but to a lesser degree than Aβ42 concentration, in Aβ42/Aβ40 mixtures.

Authors:  Shana E Terrill-Usery; Benjamin A Colvin; Richard E Davenport; Michael R Nichols
Journal:  Arch Biochem Biophys       Date:  2016-03-21       Impact factor: 4.013

7.  Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease.

Authors:  Weiguo Peng; Thiyagarajan M Achariyar; Baoman Li; Yonghong Liao; Humberto Mestre; Emi Hitomi; Sean Regan; Tristan Kasper; Sisi Peng; Fengfei Ding; Helene Benveniste; Maiken Nedergaard; Rashid Deane
Journal:  Neurobiol Dis       Date:  2016-05-24       Impact factor: 5.996

8.  Pulsed hydrogen-deuterium exchange mass spectrometry probes conformational changes in amyloid beta (Aβ) peptide aggregation.

Authors:  Ying Zhang; Don L Rempel; Jun Zhang; Anuj K Sharma; Liviu M Mirica; Michael L Gross
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

Review 9.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun

10.  Isolated amyloid-β(1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia.

Authors:  Geeta S Paranjape; Lisa K Gouwens; David C Osborn; Michael R Nichols
Journal:  ACS Chem Neurosci       Date:  2012-01-09       Impact factor: 4.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.